{"id":"activated-t-lymphocyte","safety":{"commonSideEffects":[{"rate":"null","effect":"Immune-related adverse events"}]},"_chembl":{"chemblId":"CHEMBL2106049","moleculeType":"Small molecule","molecularWeight":"12.01"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Activated T lymphocytes work by recognizing and binding to specific antigens, which triggers a cascade of immune responses to eliminate the pathogen. This process involves the activation of various immune cells, including T cells, B cells, and macrophages, which work together to eliminate the infection.","oneSentence":"Activated T lymphocytes are a type of immune cell that play a key role in the body's defense against infection and disease.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:18:49.649Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of various cancers"}]},"trialDetails":[{"nctId":"NCT03721068","phase":"PHASE1","title":"Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-02-19","conditions":"Neuroblastoma, Osteosarcoma","enrollment":18},{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma","enrollment":6452},{"nctId":"NCT03533816","phase":"PHASE1","title":"Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide","status":"RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2020-01-31","conditions":"Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia","enrollment":38},{"nctId":"NCT03910452","phase":"EARLY_PHASE1","title":"Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-10-28","conditions":"Chronic Granulomatous Disease","enrollment":4},{"nctId":"NCT02503423","phase":"PHASE1, PHASE2","title":"Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2015-07-14","conditions":"Solid Tumors, Lymphoma","enrollment":253},{"nctId":"NCT07101328","phase":"PHASE1","title":"A Study of LY4152199 in Participants With Previously Treated B-cell Cancers (BAF_FRontier-1 )","status":"NOT_YET_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-06","conditions":"Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse","enrollment":215},{"nctId":"NCT03827343","phase":"","title":"Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-01-23","conditions":"Macrophage Activation Syndrome, Primary Hemophagocytic Lymphohistiocytosis","enrollment":500},{"nctId":"NCT07175441","phase":"PHASE2","title":"Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Riboscience, LLC.","startDate":"2026-04","conditions":"Advanced Unresectable Hepatocellular Carcinoma","enrollment":220},{"nctId":"NCT06071624","phase":"PHASE1","title":"Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.","status":"RECRUITING","sponsor":"Huda Salman","startDate":"2024-02-21","conditions":"Chronic Myelomonocytic Leukemia","enrollment":30},{"nctId":"NCT05098132","phase":"PHASE1, PHASE2","title":"Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers","status":"RECRUITING","sponsor":"Synthekine","startDate":"2022-01-25","conditions":"Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC","enrollment":364},{"nctId":"NCT07481136","phase":"PHASE1","title":"64Cu-GRIP B in Patients With Acute Myocarditis","status":"NOT_YET_RECRUITING","sponsor":"Javid Moslehi, MD","startDate":"2026-08","conditions":"Acute Myocarditis","enrollment":10},{"nctId":"NCT07477366","phase":"PHASE2","title":"Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2026-04","conditions":"Relapsed B-Cell Non-Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT06823596","phase":"NA","title":"The T Cell Activator of Cell Killing (\"TACK\") IT ON\" STUDY","status":"RECRUITING","sponsor":"University of Toronto","startDate":"2025-01-14","conditions":"Hiv","enrollment":26},{"nctId":"NCT07475182","phase":"EARLY_PHASE1","title":"Exploratory Clinical Study of Targeted Activated DC and CAR-T Therapy in Advanced Solid Cancers","status":"RECRUITING","sponsor":"Hainan Cancer Hospital","startDate":"2025-12-06","conditions":"Advanced Solid Cancers","enrollment":10},{"nctId":"NCT06483048","phase":"PHASE1","title":"MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-09-20","conditions":"Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma","enrollment":12},{"nctId":"NCT07137494","phase":"PHASE1","title":"A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-08-14","conditions":"Primary Central Nervous System (CNS) Lymphoma, Secondary Central Nervous System Lymphoma","enrollment":12},{"nctId":"NCT07125872","phase":"PHASE2","title":"Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-11-11","conditions":"Relapsed B-Cell Non Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT06946680","phase":"PHASE1","title":"IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Pediatric High-grade Glioma (HGG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2025-03-18","conditions":"High-grade Glioma","enrollment":18},{"nctId":"NCT07464951","phase":"PHASE1","title":"CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Stephan Grupp MD PhD","startDate":"2026-04-01","conditions":"Acute Myeloid Leukemia (AML)","enrollment":30},{"nctId":"NCT07461181","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, PK, PD, and Preliminary Efficacy of CS01 in Patients With Locally Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-12-30","conditions":"Locally Advanced or Metastatic Solid Tumors","enrollment":10},{"nctId":"NCT07257419","phase":"PHASE1","title":"CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-03-03","conditions":"Relapsed Pediatric ALL, Hematopoietic Cell Transplantation, Hematologic Malignancy","enrollment":60},{"nctId":"NCT05353530","phase":"PHASE1","title":"IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2023-07-25","conditions":"Glioblastoma Multiforme, Glioblastoma","enrollment":39},{"nctId":"NCT07217301","phase":"PHASE3","title":"IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed","status":"RECRUITING","sponsor":"Fortvita Biologics (USA)Inc.","startDate":"2025-11-26","conditions":"iO Resistant sqNSCLC","enrollment":600},{"nctId":"NCT03849651","phase":"PHASE2","title":"TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-01-31","conditions":"Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)","enrollment":69},{"nctId":"NCT06692426","phase":"PHASE1","title":"Trial of Cell Based Therapy for DMD","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2025-03-20","conditions":"Duchenne Muscular Dystrophy","enrollment":8},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT07223541","phase":"PHASE2","title":"Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma","status":"RECRUITING","sponsor":"University of Oklahoma","startDate":"2026-01-15","conditions":"Clear Cell Renal Cell Carcinoma","enrollment":72},{"nctId":"NCT07437534","phase":"PHASE4","title":"Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical Treatment of Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"Hayat Abad Medical Complex, Peshawar","startDate":"2026-03-01","conditions":"Atopic Dermatitis","enrollment":148},{"nctId":"NCT04969887","phase":"PHASE2","title":"Combination Immunotherapy in Rare Cancers Under InvesTigation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Olivia Newton-John Cancer Research Institute","startDate":"2021-08-03","conditions":"Advanced Biliary Tract Cancer, Neuroendocrine Tumors, Female Reproductive System Neoplasm","enrollment":240},{"nctId":"NCT03272334","phase":"PHASE1, PHASE2","title":"Her2-BATS and Pembrolizumab in Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Virginia","startDate":"2017-12-29","conditions":"Metastatic Breast Cancer","enrollment":22},{"nctId":"NCT05255601","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2022-09-13","conditions":"Lymphoma, Non-Hodgkin, Hodgkin Disease","enrollment":5},{"nctId":"NCT02744287","phase":"PHASE1","title":"Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2016-11-30","conditions":"Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer","enrollment":52},{"nctId":"NCT07416240","phase":"EARLY_PHASE1","title":"Exploratory Clinical Study of Claudin18.2-Targeted Activated DC and CAR-T Therapy in Advanced Pancreatic Cancer.","status":"RECRUITING","sponsor":"Hainan Cancer Hospital","startDate":"2026-02-18","conditions":"Advanced Pancreatic Cancer","enrollment":10},{"nctId":"NCT06191887","phase":"PHASE1","title":"B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-03-18","conditions":"B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":27},{"nctId":"NCT05676697","phase":"PHASE1","title":"PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy","status":"TERMINATED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-01-13","conditions":"Autoimmune Hemolytic Anemia, Failure of Two Rounds of Treatment","enrollment":4},{"nctId":"NCT04690595","phase":"PHASE1","title":"BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL","status":"ACTIVE_NOT_RECRUITING","sponsor":"PeproMene Bio, Inc.","startDate":"2021-05-18","conditions":"Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia","enrollment":24},{"nctId":"NCT04963283","phase":"PHASE2","title":"Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2021-06-23","conditions":"Colorectal Adenocarcinoma, Colon Cancer, Colon Adenocarcinoma","enrollment":48},{"nctId":"NCT04806347","phase":"PHASE1","title":"Alpha/Beta T-cell Depleted Blood-forming Stem Cell Transplant From Related or Unrelated Donors for Blood Diseases in Children and Young Adults","status":"NOT_YET_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2026-04","conditions":"Blood Disease","enrollment":12},{"nctId":"NCT07105059","phase":"PHASE1","title":"A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-08-08","conditions":"Multiple Myeloma","enrollment":18},{"nctId":"NCT04080804","phase":"PHASE2","title":"Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer","status":"RECRUITING","sponsor":"Dan Zandberg","startDate":"2019-12-20","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":80},{"nctId":"NCT03965468","phase":"PHASE2","title":"Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2019-11-19","conditions":"Non-small Cell Lung Cancer, Stage IV, Oligometastasis","enrollment":96},{"nctId":"NCT05872854","phase":"PHASE2","title":"Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light","status":"COMPLETED","sponsor":"Ellen Kim, MD","startDate":"2023-08-21","conditions":"Cutaneous T Cell Lymphoma, Mycosis Fungoides","enrollment":10},{"nctId":"NCT07392073","phase":"","title":"Peripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-04","conditions":"Non-Small Cell Lung Cancer, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma","enrollment":80},{"nctId":"NCT01625351","phase":"PHASE1","title":"A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2012-08-20","conditions":"Ewing Sarcoma, Gastrointestinal Tumor, Germ Cell Tumor","enrollment":23},{"nctId":"NCT03203473","phase":"PHASE2","title":"Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Toni Choueiri, MD","startDate":"2017-10-26","conditions":"Renal Cancer","enrollment":85},{"nctId":"NCT05418972","phase":"PHASE2","title":"A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2023-08-14","conditions":"Stage II Melanoma","enrollment":20},{"nctId":"NCT07386912","phase":"","title":"Investigation of the Effects of Oxidized Antigens on the T-Cell Response and the Epigenetic Reprogramming of Neutrophils in Lung Diseases - OXIGENE -","status":"NOT_YET_RECRUITING","sponsor":"Research Center Borstel","startDate":"2026-02-01","conditions":"Asthma, COPD, Bacterial Pneumonia","enrollment":100},{"nctId":"NCT05460533","phase":"PHASE2","title":"A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-07-12","conditions":"B-cell Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT00709033","phase":"PHASE1","title":"T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2009-07","conditions":"Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia","enrollment":3},{"nctId":"NCT04745559","phase":"PHASE2","title":"Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-02-18","conditions":"Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (TFL)","enrollment":26},{"nctId":"NCT03279692","phase":"PHASE2","title":"Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2017-11-07","conditions":"High Grade Meningioma","enrollment":26},{"nctId":"NCT03356470","phase":"","title":"Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2017-11-02","conditions":"Melanoma","enrollment":5},{"nctId":"NCT04989946","phase":"PHASE1, PHASE2","title":"Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2021-12-16","conditions":"Prostate Cancer","enrollment":60},{"nctId":"NCT07087002","phase":"PHASE1","title":"GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults","status":"RECRUITING","sponsor":"Stanford University","startDate":"2025-08-28","conditions":"Medulloblastoma, Central Nervous System Embryonal Tumor, Refractory Medulloblastoma","enrollment":18},{"nctId":"NCT07319676","phase":"PHASE1, PHASE2","title":"Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas","status":"NOT_YET_RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2026-01-31","conditions":"B-cell Lymphoma Refractory","enrollment":30},{"nctId":"NCT03829540","phase":"PHASE1","title":"CD4CAR for CD4+ Leukemia and Lymphoma","status":"RECRUITING","sponsor":"Huda Salman","startDate":"2020-07-09","conditions":"T-cell Lymphoma, T-cell Leukemia","enrollment":20},{"nctId":"NCT07189936","phase":"PHASE2","title":"Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2025-12-18","conditions":"Post-Acute COVID-19 Syndrome, Postural Tachycardia Syndrome (POTS), SARS CoV 2 Infection","enrollment":50},{"nctId":"NCT06197672","phase":"PHASE1","title":"Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant","status":"RECRUITING","sponsor":"Huda Salman","startDate":"2024-03-19","conditions":"Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT03333616","phase":"PHASE2","title":"Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-12-28","conditions":"Genitourinary Cancer, Adrenocortical Carcinoma, Non-urothelial Bladder","enrollment":100},{"nctId":"NCT06962631","phase":"PHASE3","title":"V-IMMUNE® for Immune Thrombocytopenia","status":"RECRUITING","sponsor":"On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.","startDate":"2025-07-18","conditions":"Immune Thrombocytopenia (ITP)","enrollment":31},{"nctId":"NCT06954441","phase":"PHASE3","title":"V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency","status":"RECRUITING","sponsor":"On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.","startDate":"2025-08-15","conditions":"Immunodeficiencies, Primary Immunodeficiencies (PID), Agammaglobulinemia","enrollment":50},{"nctId":"NCT06731504","phase":"EARLY_PHASE1","title":"HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT","status":"RECRUITING","sponsor":"Duke University","startDate":"2025-11-12","conditions":"Hematologic Malignancy","enrollment":10},{"nctId":"NCT04530123","phase":"PHASE2","title":"Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet","status":"COMPLETED","sponsor":"Takeda","startDate":"2022-06-23","conditions":"Celiac Disease","enrollment":102},{"nctId":"NCT07345208","phase":"PHASE2, PHASE3","title":"Safety and Immunogenicity of ID vs IM Rabies Vaccine","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-12-15","conditions":"Rabies","enrollment":90},{"nctId":"NCT05544968","phase":"PHASE1","title":"Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2026-03","conditions":"Hodgkin Disease, CD30-Positive Diffuse Large B-Cell Lymphoma, CD30+ Anaplastic Large Cell Lymphoma","enrollment":42},{"nctId":"NCT05400109","phase":"PHASE1","title":"Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"David Wald","startDate":"2023-04-26","conditions":"Non Hodgkin Lymphoma","enrollment":21},{"nctId":"NCT06295159","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-05-17","conditions":"Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma","enrollment":90},{"nctId":"NCT07321847","phase":"PHASE2, PHASE3","title":"Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases","status":"NOT_YET_RECRUITING","sponsor":"Immunophotonics, Inc.","startDate":"2026-05","conditions":"Colorectal Cancer (CRC), Colon Cancer Liver Metastases, Rectal Cancer","enrollment":717},{"nctId":"NCT01853631","phase":"PHASE1","title":"Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2014-02","conditions":"Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia","enrollment":64},{"nctId":"NCT07266116","phase":"PHASE1, PHASE2","title":"Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients","status":"RECRUITING","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","startDate":"2025-12-26","conditions":"Systemic Light Chain Amyloidosis","enrollment":70},{"nctId":"NCT07052370","phase":"PHASE1","title":"TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-09-25","conditions":"Hematologic Malignancy","enrollment":30},{"nctId":"NCT06219616","phase":"NA","title":"Prediction of BK Virus Reactivation in Kidney Transplant Recipient","status":"COMPLETED","sponsor":"King Chulalongkorn Memorial Hospital","startDate":"2023-05-01","conditions":"Kidney Transplant Infection, BK Virus Infection, BK Virus Nephropathy","enrollment":80},{"nctId":"NCT07307053","phase":"PHASE1, PHASE2","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":600},{"nctId":"NCT04165941","phase":"PHASE1","title":"Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2020-02-11","conditions":"Brain Tumor Adult","enrollment":22},{"nctId":"NCT06824064","phase":"PHASE2","title":"Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer","status":"RECRUITING","sponsor":"Riboscience, LLC.","startDate":"2025-01-17","conditions":"Metastatic Colorectal Cancer, Advanced Colorectal Cancer","enrollment":150},{"nctId":"NCT04670068","phase":"PHASE1","title":"Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2021-01-27","conditions":"Epithelial Ovarian Cancer","enrollment":4},{"nctId":"NCT03388632","phase":"PHASE1","title":"Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-02-05","conditions":"Metastatic Solid Tumors, Treatment-Refractory Cancers","enrollment":31},{"nctId":"NCT04688658","phase":"PHASE1, PHASE2","title":"Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma","status":"TERMINATED","sponsor":"John Kirkwood","startDate":"2021-10-06","conditions":"Unresectable Melanoma","enrollment":13},{"nctId":"NCT03622788","phase":"PHASE1, PHASE2","title":"Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-08-08","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia","enrollment":16},{"nctId":"NCT04664179","phase":"PHASE1","title":"EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2022-10-31","conditions":"EBV-Related Hodgkin Lymphoma, EBV-Related Lymphoproliferative Disorder, EBV Related Non-Hodgkin's Lymphoma","enrollment":52},{"nctId":"NCT03952637","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis","status":"RECRUITING","sponsor":"National Human Genome Research Institute (NHGRI)","startDate":"2019-08-19","conditions":"Lysosomal Diseases, Gangliosidosis, GM1","enrollment":54},{"nctId":"NCT07179679","phase":"PHASE1","title":"A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-12-09","conditions":"Multiple Myeloma","enrollment":42},{"nctId":"NCT05329337","phase":"NA","title":"Link Between the Peripheral Mononuclear Cells' Capacity to Induce Insulin Resistance and Hyperinsulinemia","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2022-06-27","conditions":"Insulin Resistance, Hyperinsulinism, Immune System","enrollment":30},{"nctId":"NCT02374242","phase":"PHASE2","title":"Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2014-11-04","conditions":"Melanoma, Brain Metastases","enrollment":76},{"nctId":"NCT07271121","phase":"PHASE2","title":"Study of CART Cell (MB-CART19.1) in Patients With Relapsed or Refractory CD19 Positive NHL","status":"RECRUITING","sponsor":"King Hussein Cancer Center","startDate":"2025-02-12","conditions":"Non-Hodgkin Lymphoma Refractory/ Relapsed","enrollment":26},{"nctId":"NCT03367962","phase":"PHASE1","title":"Detection of Graft Versus Host Disease With [18F]F-AraG","status":"COMPLETED","sponsor":"CellSight Technologies, Inc.","startDate":"2018-05-15","conditions":"Graft Versus Host Disease","enrollment":9},{"nctId":"NCT03696784","phase":"PHASE1","title":"Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-03-12","conditions":"Lymphoma, Lymphoma, B-Cell, Immune System Diseases","enrollment":19},{"nctId":"NCT05089370","phase":"PHASE1, PHASE2","title":"Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2022-06-20","conditions":"Malignant Melanoma","enrollment":8},{"nctId":"NCT03117751","phase":"PHASE2, PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma","enrollment":790},{"nctId":"NCT07264075","phase":"PHASE3","title":"Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN","status":"NOT_YET_RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2026-01","conditions":"Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)","enrollment":780},{"nctId":"NCT05010005","phase":"PHASE1","title":"A Study of Ruxolitinib and Duvelisib in People With Lymphoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-08-12","conditions":"T-cell Lymphomas, NK-Cell Lymphomas, T-cell Prolymphocytic Leukemia","enrollment":70},{"nctId":"NCT07249073","phase":"EARLY_PHASE1","title":"CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-03-28","conditions":"Multiple Myeloma","enrollment":9},{"nctId":"NCT03307785","phase":"PHASE1","title":"Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2017-10-12","conditions":"Neoplasms, Metastatic Cancer, Advanced Cancer","enrollment":60},{"nctId":"NCT07242482","phase":"","title":"Circulating Immune Markers for Prognostic Evaluation in Postoperative Lung Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Zhao Jun","startDate":"2025-12-17","conditions":"Lung Cancer (Diagnosis), Biomarkers / Blood","enrollment":200},{"nctId":"NCT05370430","phase":"PHASE1","title":"BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL","status":"RECRUITING","sponsor":"PeproMene Bio, Inc.","startDate":"2022-06-13","conditions":"Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma","enrollment":36},{"nctId":"NCT07240194","phase":"PHASE2","title":"The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-09-01","conditions":"Large B-cell Lymphoma, TP53","enrollment":24},{"nctId":"NCT06455917","phase":"PHASE2","title":"TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-01-22","conditions":"Non-Small Cell Lung Cancer, Lung Cancer (NSCLC)","enrollment":30},{"nctId":"NCT04520711","phase":"PHASE1","title":"Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Providence Health & Services","startDate":"2022-02-08","conditions":"Malignant Epithelial Neoplasms","enrollment":24},{"nctId":"NCT03573700","phase":"PHASE1, PHASE2","title":"Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2018-07-24","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory","enrollment":24},{"nctId":"NCT01857934","phase":"PHASE2","title":"Therapy for Children With Advanced Stage Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-07-05","conditions":"Neuroblastoma","enrollment":153}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":152,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Immuncell-LC"],"phase":"phase_2","status":"active","brandName":"Activated T lymphocyte","genericName":"Activated T lymphocyte","companyName":"GC Cell Corporation","companyId":"gc-cell-corporation","modality":"Biologic","firstApprovalDate":"","aiSummary":"Activated T lymphocytes are a type of immune cell that play a key role in the body's defense against infection and disease. Used for Treatment of various cancers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}